Global Atherectomy Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Device Type (Atherectomy Devices, Angioplasty Balloon Catheters, Stents, Intravascular Ultrasound Catheters, Optical Coherence Tomography Catheters, Drug-Coated Balloons, Embolic Protection Devices, Thrombectomy Devices, Aortic Stent Grafts, Endovascular Grafts, Laser Atherectomy Devices, Orbital Atherectomy Systems, Rotational Atherectomy Devices, Directional Atherectomy Devices, Chronic Total Occlusion Devices), By Application (Peripheral Artery Disease Treatment Devices, Coronary Artery Disease Intervention Devices, Carotid Artery Disease Intervention Device, Renal Artery Disease Intervention Devices, Aortic Atherosclerosis Intervention Devices), By End-users (Cardiac Catheterization Labs, Interventional Radiology Departments, Vascular Surgery Centres, Cardiology Clinics, Academic Research Institutions), and Region Forecast 2020-2031

Atherectomy Devices Market size was valued at approximately US$ 1.02 billion in 2024 and is projected to reach around US$ 1.85 billion by 2031 growing at an expected 6.5% CAGR from 2025-2031. Moreover, the U.S. Atherectomy Devices Market is anticipated to grow significantly, reaching an estimated US$ 827 million by 2031. The market is demonstrating steady growth due to rising incidence of coronary and peripheral artery disease, particularly in diabetic patients and geriatric patients. Atherectomy for the excision of atherosclerotic plaque from the arterial wall is gaining greater acceptability in the clinic as minimally invasive treatment compared to conventional therapy. With increasing prevalence of cardiovascular disease, healthcare systems are turning to newer interventional technologies that will help in achieving reduced recovery times, improved procedural success, and reduced restenosis. All these are helping in favorable situations for hospitals, ambulatory surgery centers, and specialized cardiovascular clinics to utilize atherectomy devices.

Technology advances in the form of directional, orbital, laser, and rotational atherectomy systems are improving procedural efficacy while tempering lesion complexity and anatomical subtlety. Industry participants are judiciously developing product upgrade, clinical assistance, and geographic presence to increase competitive visibility. Regulatory agencies and payers also are becoming more open to reimbursement for device-based procedures, particularly as evidence accumulates on their long-term value-cost. Whereas regulatory compliance and price pressure remain, if ever so much so, the huge issues, the burgeoning demand for precise, catheter-based plaque elimination products continues solidly at the growth anchor for mature and emerging economies alike.

Facts & Figures

• Roughly 805,000 Americans experience a heart attack every year, and according to the Centers for Disease Control and Prevention (2023), the top underlying cause is reported to be atherosclerosis.
• Atherosclerosis is the causative agent of myocardial infarction, stroke, PAD, and other cardiovascular events, therefore, clinical demand for associated treatment procedures like atherectomy devices is high.
• Peripheral Arterial Disease (PAD) affects roughly 8 to 12 million Americans, and of the diagnosed cases in adults over 40 years old, there are 6.5 million.
• In 2020, an estimated 116 million American adults had hypertension, which was reported through CDC data.
• The 2020 CDC's National Diabetes Report reported 34.2 million Americans with diabetes, and approximately 88 million with prediabetic indicators.

Key Developments

• In May 2025, Becton, Dickinson and Company (BD) announced the start of XTRACT, a post-market multi-center registry trial to assess real-world outcomes for application of the Rotarex Atherectomy System in treating PAD lesions of patients in the US.
• In May 2025, Reflow Medical's Spur Peripheral Retrievable Stent System was granted FDA de novo classification, marking its entry into the market as a novel peripheral artery disease (PAD) device with no existing equivalent.
• In Nov 2024, Philips conducted its first U.S. patient treatment with its new designed laser-based atherectomy device, combining two PAD procedures into one; the event was the kickoff of the THOR IDE study at the Cardiovascular Institute of the South.
• In Aug 2024, Avinger, Inc. launched the Pantheris LV, the first and only image-guided directional atherectomy system globally, commercially available for the treatment of PAD in all customer accounts.

Atherectomy Devices Market Segmentation

Based on the device type

• Atherectomy Devices
• Angioplasty Balloon Catheters
• Stents (Bare-Metal, Drug-Eluting, Bioresorbable)
• Intravascular Ultrasound (IVUS) Catheters
• Optical Coherence Tomography (OCT) Catheters
• Drug-Coated Balloons
• Embolic Protection Devices
• Thrombectomy Devices
• Aortic Stent Grafts
• Endovascular Grafts
• Laser Atherectomy Devices
• Orbital Atherectomy Systems
• Rotational Atherectomy Devices
• Directional Atherectomy Devices
• Chronic Total Occlusion (CTO) Devices

Rotational atherectomy devices are the most driven category of the total atherectomy market among the diverse device types. Treatments for highly calcified lesions and greater precision and safety profiles place them in a strong position within interventional cardiology and peripheral vascular interventions. Adoption is fuelled by emerging technologies that improve device performance and operator control and greater procedural volumes for calcified arterial disease. In addition, impressive clinical evidence favourable to improved patient results and broadening applications in coronary and peripheral procedures further validate rotational atherectomy devices as the market's growth driver of choice.

Based on the application

• Peripheral Artery Disease (PAD) Treatment Devices
• Coronary Artery Disease (CAD) Intervention Devices
• Carotid Artery Disease Intervention Devices
• Renal Artery Disease Intervention Devices
• Aortic Atherosclerosis Intervention Devices

Among all the application segments, Peripheral Artery Disease (PAD) Treatment Devices dominate the atherectomy devices market globally due to the rising incidence of PAD, particularly among elderly and diabetic patients. PAD's complexity of lesion morphology and consequent high rate of critical limb ischemia necessitate delicate, minimally invasive atherectomy procedures to reopen flow and avoid amputation. Growing perception of PAD complication risks, and technological advancements that improve accessibility of lesions and the safety of procedures, also fuel adoption. Also, cost-effectiveness of atherectomy as a PAD treatment, and increasing outpatient treatment options, put this segment at the forefront of market space growth drivers.

Based on the end user

• Cardiac Catheterization Labs
• Interventional Radiology Departments
• Vascular Surgery Centers
• Cardiology Clinics
• Academic Research Institution

Among all end-user markets, Cardiac Catheterization Labs are the biggest atherectomy devices markets worldwide because they are centrally involved in the diagnosis and treatment of advanced cardiovascular disease. Cardiac Catheterization Labs provide an environment with sophisticated imaging and intervention facilities, allowing for detailed plaque removal and reconstruction of vessels. Large number of percutaneous coronary interventions done here and rising acceptance of minimally invasive procedures fuel demand for atherectomy devices. In addition, rising same-day discharge and outpatient intervention pressure further supports dependence upon catheterization laboratories as main sites for atherectomy procedures, solidifying their position of central market worldwide.